Lyra Therapeutics (OTCMKTS:LYRA) Stock Price Up 2,400% – Still a Buy?

Shares of Lyra Therapeutics, Inc. (OTCMKTS:LYRA) were up 2,400% during mid-day trading on Wednesday . The company traded as high as $0.25 and last traded at $0.25. 959 shares were traded during mid-day trading, a decline of 18% from the average session volume of 1,168 shares. The stock had previously closed at $0.01.

Lyra Therapeutics Stock Performance

The company has a 50 day simple moving average of $0.44 and a two-hundred day simple moving average of $0.70. The firm has a market cap of $442,500.00, a PE ratio of -0.01 and a beta of 0.72.

Institutional Investors Weigh In On Lyra Therapeutics

A number of large investors have recently bought and sold shares of LYRA. Artia Global Partners LP acquired a new position in Lyra Therapeutics in the 4th quarter worth approximately $27,000. DRW Securities LLC purchased a new position in Lyra Therapeutics during the 4th quarter worth approximately $52,000. Citadel Advisors LLC acquired a new stake in Lyra Therapeutics during the 3rd quarter valued at approximately $128,000. Bank of America Corp DE lifted its stake in Lyra Therapeutics by 33.7% during the 2nd quarter. Bank of America Corp DE now owns 28,542 shares of the company’s stock valued at $256,000 after acquiring an additional 7,190 shares during the period. Finally, Sabby Management LLC boosted its holdings in shares of Lyra Therapeutics by 37.2% in the 4th quarter. Sabby Management LLC now owns 175,158 shares of the company’s stock valued at $539,000 after acquiring an additional 47,534 shares during the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

About Lyra Therapeutics

Lyra Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted drug delivery therapies for diseases of the ear, nose and throat (ENT). Leveraging its proprietary Therapeutic Drug Delivery (TDD) platform, the company designs bioresorbable, steroid-eluting implants that provide sustained, localized release of medication directly to affected tissue. This approach aims to improve patient outcomes by reducing the need for repeated administration and minimizing systemic side effects.

The company’s lead product candidate, LYR-210, is an implantable matrix that delivers the corticosteroid mometasone furoate over several months to treat chronic rhinosinusitis (CRS).